Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | GLS | O94925 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24846063 | 0.88 | TSHR (0.61) | RAB9AGLSKMT2AMEN1TSHR | |
| SCHEMBL24846070 | 0.85 | TSHR (0.61) | KMT2AMEN1TSHRSMN1; SMN2POLB | |
| SCHEMBL24846080 | 0.84 | TSHR (0.57) | RAB9AKMT2AMEN1TSHRNPC1 | |
| SCHEMBL24846085 | 0.82 | TSHR (0.57) | RAB9AKMT2AMEN1TSHRNPC1 | |
| SCHEMBL24846549 | 0.81 | RAB9A (0.60) | RAB9AGLSKMT2AMEN1TSHR | |
| SCHEMBL24952911 | 0.80 | RAB9A (0.52) | RAB9AGLSKMT2AMEN1DGAT1 | |
| SCHEMBL29846147 | 0.80 | RAB9A (0.52) | RAB9AGLSKMT2AMEN1DGAT1 | |
| SCHEMBL24846114 | 0.80 | KMT2A (0.48) | RAB9AGLSKMT2AMEN1TSHR | |
| SCHEMBL29047592 | 0.79 | GLS (0.60) | RAB9AGLSKMT2AMEN1TSHR | |
| SCHEMBL24846086 | 0.76 | KMT2A (0.48) | RAB9AGLSKMT2AMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002336-A1 | MrgprX2 Antagonists and Uses Thereof | DERMIRA, INC. | 2023-01-05 | — | — | US | disclosed |
| CN-114728919-A | MrgprX2 antagonists and uses thereof | 德米拉公司 | 2022-07-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002336-A1 | MrgprX2 Antagonists and Uses Thereof | MRGPRX2, MRGPRX1, MRGPRX4 | RAB9A 2006/4885GLS 1237/4885KMT2A 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.